Abstract 417P
Background
Soft tissue sarcomas belong to a heterogeneous group of malignant tumours of mesenchymal origin which constitutes <1% of adult cancers and 12% of paediatric cancers. This study highlights the clinical spectrum of sarcomas, various histological patterns and survival outcomes. The intent is to study retrospectively the clinicopathologic profile and survival outcomes of soft tissue sarcomas and bone sarcomas treated with radiation therapy at a Regional Cancer Centre from South India.
Methods
The clinical and treatment details of patients were collected retrospectively for the period 2014 -2017 and were analysed using descriptive statistics. Survival analysis was done using Kaplan-Meir Analysis.
Results
The median age of presentation was 42 years (Range 2-80). Among the 123 patients studied , 54.5%(n = 67) were males and 45.5%(n = 56) were females. The most common presenting complaint was swelling 69% (n = 85) followed by pain 38.2% (n = 47). The most common site of involvement was extremity 48% (n = 59). Other more commonly involved sites were Genitourinary 7.3%(n = 9) and uterus 4.9% (n = 6). The most common histology was Ewing Sarcoma 14.6%(n = 18) followed by Undifferentiated Pleomorphic Sarcoma 13.8% (n = 17). Around 17.9%(n = 22) had metastatic disease at presentation, of which metastasis to lungs (n = 13) was most common, followed by bone (n = 8) and liver(n = 4). The intent of Radiation Therapy was Adjuvant 54.4%(n = 67), Palliative 32.2%(n = 21), Radical 13.8 (n = 17) and Neoadjuvant 6.5%(n = 8). Only 65.9%(n = 81) completed their intended radiation therapy. 91.9% (n = 113) received External Beam Radiation Therapy and 13% (n = 16) received Brachytherapy. Around 48.8% (n = 60) underwent surgery and 66.6% (n = 82) received some form of chemotherapy. The Mean Overall Survival was 50.4 months (95% CI 44.2-56.5 months). Median OS was not reached.
Conclusions
As per our study, the most common histology was Ewing Sarcoma, followed by Undifferentiated Pleomorphic sarcoma. Approximately 70% of sarcoma patients referred to Radiation Oncology department were for Curative intent whereas 30% with palliative intent and this has led to Mean OS of 50.4 months. At the same time with limited follow up data and the low number of events, the Median OS was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract